title: New pancreatic adenocarcinoma in a Crohn's patient treated with tumor necrosis factor (TNF) inhibitors for 6 months.
authors.affiliation: Internal Medicine Department, University of South Florida, Morsani College of Medicine, Tampa, FL, USA, rpatel19@health.usf.edu.
authors.forename: Rupal
authors.initials: R
authors.lastname: Patel
authors.forename: Shanil
authors.initials: S
authors.lastname: Lara
authors.forename: Jean
authors.initials: J
authors.lastname: Johnson
authors.forename: Prasad
authors.initials: P
authors.lastname: Kulkarni
mesh_terms: D000068879:Adalimumab; D000230:Adenocarcinoma / Q000139:chemically induced* / Q000473:pathology; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects*; D003424:Crohn Disease / Q000188:drug therapy*; D006801:Humans; D000069285:Infliximab; D008297:Male; D010190:Pancreatic Neoplasms / Q000139:chemically induced* / Q000473:pathology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab